Clinical trials: Esomeprazole, completed
Gastroesophageal Reflux Disease (GERD)
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients 12 to 17 years of age…
- Trial name
- NCT00241501
- Testing
- Esomeprazole (Nexium)
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
To investigate the impact of initial treatment duration (4-week versus 8-week)of Esomeprazole (40mg) on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
- Trial name
- NCT01874535
- Testing
- Esomeprazole 40 mg
- Where
- Taiwan
- Volunteers
- 408 people
- Sponsor
- Chang Gung Memorial Hospital
Hospitalized Cases of Angioneurotic Oedema, Pneumonia
Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists
The purpose of this study is 1. To describe patient characteristics and drug usage among children that are prescribed esomeprazole for the first time and to compare them with patients who are prescribed other proton pump…
- Conditions
- Hospitalized Cases of Angioneurotic Oedema, Pneumonia, Gastroenteritis, Failure to Thrive
- Trial name
- NCT01338363
- Where
- Netherlands
- Volunteers
- 23,470 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Phase 3/Safety & Efficacy of Esomeprazole in Infants
The purpose of this study is to look at the improvement of a once a day dose of esomeprazole for reducing the signs and symptoms of infants with gastroesophageal reflux disease (GERD).
- Trial name
- NCT00468559
- Testing
- Open Label Run In Esomeprazole, Double Blind Esomeprazole
- Where
- 25 sites in United States, France and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis
Esomeprazole for Treatment of GERD in Pediatric Patients
To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease…
- Conditions
- Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
- Trial name
- NCT00228527
- Testing
- Esomeprazole (Nexium)
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children
This study aims to compare the recurrence rates of Esomeprazole and Lansoprazole in triple combination therapy to eradicate H.pylori infection in children.
- Trial name
- NCT05861687
- Testing
- Esomeprazole, Lansoprazole, Amoxicillin
- Where
- 2 sites in Indonesia
- Volunteers
- 51 people
- Sponsor
- Finni Kollins
Gastroesophageal Reflux
Implementation of PPI Medication PGX Testing
Using genetic information about the individual to pick the right drug for the right disease at the right dose defines personalized medicine.
- Trial name
- PGX (NCT02794844)
- Testing
- Genotype Guided PPI Dosing
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nemours Children's Clinic
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules LDA Specific Clinical Experience Investigation
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose…
- Trial name
- NCT01729182
- Where
- 47 sites in Japan
- Volunteers
- 2,363 people
- Sponsor
- AstraZeneca
Pharmacokinetics
Phase 1 Pharmacokinetics of Intravenous Nexium in Children
The purpose of this research study is to evaluate how much of repeated once daily intravenous (IV, meaning through a vein) doses of esomeprazole gets into the bloodstream of hospitalized children aged 0-17 years old that require…
- Trial name
- NCT00474019
- Testing
- esomeprazole
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Repeatedly Recurring Esophagitis, Relapsing Reflux Esophagitis
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
- Trial name
- NCT01562639
- Where
- 46 sites in Japan
- Volunteers
- 647 people
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection
This study intends to collect the clinical data of patients with Helicobacter pylori infection, and to observe and count the high-dose double therapy and the traditional quadruple / triple therapy ( i.e., esomeprazole +…
- Trial name
- NCT06250634
- Testing
- esomeprazole + amoxicillin, esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent, Vonoprazan + amoxicillin
- Where
- China
- Volunteers
- 806 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Helicobacter Pylori Infection, Chronic Gastritis
Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication
The purpose of this study was to evaluate the efficacy and safety of the triple therapy of berberine hydrochloride, vonorasan and amoxicillin for the primary eradication of Helicobacter pylori.It is hypothesized that berberine…
- Trial name
- NCT06514274
- Testing
- Berberine, Vonoprazan, Amoxicillin
- Where
- China
- Volunteers
- 558 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital of Digestive Diseases
Erosive Esophagitis
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
- Trial name
- EE (NCT05267613)
- Testing
- Nexium 20mg, Nexium 10mg
- Where
- 41 sites in United States, Argentina and 8 more
- Volunteers
- 53 people
- Sponsor
- AstraZeneca
H. Pylori Infection
Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori
Patients infected with H. pylori are treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid or esomeprazole 20 mg bid, AMPC 750 mg bid and CAM 200 mg bid. Eradication rates are compared.
- Trial name
- NCT02767479
- Testing
- rabeprazole-based regimen, esomeprazole^based regimen
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Hamamatsu University
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation
The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with…
- Trial name
- NCT01562600
- Where
- 46 sites in Japan
- Volunteers
- 1,634 people
- Sponsor
- AstraZeneca
Homeostasis, Bone and Bones
Effect of Dexlansoprazole on Bone Homeostasis
The purpose of this study is to evaluate the effect of dexlansoprazole modified release (MR), once daily (QD), on bone homeostasis.
- Trial name
- NCT01216293
- Testing
- Dexlansoprazole, Esomeprazole
- Where
- 12 sites in United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Takeda
Familial Hypercholesterolemia
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind…
- Trial name
- NCT00355615
- Testing
- Rosuvastatin
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- AstraZeneca
Juvenile Idiopathic Arthritis (JIA)
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
- Trial name
- NCT01544114
- Testing
- VIMOVO 250/20, VIMOVO 375/20, VIMOVO 500/20
- Where
- 17 sites in United States
- Volunteers
- 46 people
- Sponsor
- Amgen
Pharmacokinetics, Voriconazole
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
The death rate in children from the invasive fungal infection called aspergillosis is more than 50%. Voriconazole is the first-line therapy for this infection.
- Trial name
- NCT01976078
- Testing
- Midazolam/Ranitidine/Esomeprazole
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Children's Hospital Los Angeles